Johnson Matthey (LON:JMAT)‘s stock had its “sell” rating restated by research analysts at UBS Group in a research note issued to investors on Thursday, investing.thisismoney.co.uk reports.
Several other equities analysts also recently issued reports on the stock. Deutsche Bank reissued a “buy” rating and set a GBX 4,500 ($58.80) price target on shares of Johnson Matthey in a report on Monday, October 8th. Berenberg Bank reissued a “buy” rating and set a GBX 4,300 ($56.19) price target on shares of Johnson Matthey in a report on Monday, September 17th. Credit Suisse Group reissued an “outperform” rating on shares of Johnson Matthey in a report on Thursday, August 23rd. Finally, Liberum Capital reissued a “buy” rating on shares of Johnson Matthey in a report on Wednesday, September 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of GBX 3,962.50 ($51.78).
Shares of JMAT stock opened at GBX 2,914 ($38.08) on Thursday. Johnson Matthey has a 12-month low of GBX 2,681 ($35.03) and a 12-month high of GBX 3,511 ($45.88).
Johnson Matthey Company Profile
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
Featured Story: Asset Allocation, Balancing Your Investments
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.